CD47 and melanoma: This suggests that resistance to vemurafenib of melanomas without upregulation of CD47 may be primarily due to mechanisms other than reactivation of ERK, such as overexpression of MAP3K8 (COT) and switch of melanoma cells towards a more mesenchymal phenotype [34–36].